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WS8.1 Lung transplant referrals and outcomes: experience of a
regional adult CF centre 2008−2013
C. Etherington1, A. Boland1, I. Clifton1, P. Whitaker1, D. Peckham1. 1St. James’s
University Hospital, Regional Adult Cystic Fibrosis Centre, Leeds, United Kingdom
Objectives: Lung transplantation is the most effective means of improving survival
and quality of life in patients with end-stage CF. Our aim was to determine outcomes
of referrals, waiting times and factors associated with a poor outcome.
Methods: Data were retrieved retrospectively from our electronic patient record
system for all adult patient referred to UK Transplant centres over a 6 year period.
Results: 48 patients [27 female, median (range) age at referral 29.7 yrs (16.5–49.5),
FEV1 25% predicted (13−41) and BMI 20.2 kg/m
2 (16.6–29.7) were referred for
lung transplantation. Median time from initial discussion to referral was 80 days
(13–1090). 3 patients died prior to ﬁrst appointment and 5 are waiting to be
seen. 40 patients were assessed and 26 accepted (4 died after ﬁrst appointment,
2 not accepted and 8 currently under follow up). Of the 26 accepted, 16 have
received a transplant [waiting time on active list 177 days (28–865)], 3 died on the
active list, 3 were removed (signiﬁcant clinical deterioration) and 4 are currently
waiting. Total referral process from initial assessment to transplant was 1.6 yrs
(0.7−3.2). Fifteen patients died during the referral process; there were no signiﬁcant
differences in clinical severity when compared to patients who were transplanted.
However patients who died during the process had a signiﬁcantly longer time
from initial discussion to local assessment [112 (13–1090) vs. 56 (29–440) days,
p = 0.0481].
Conclusion: Early discussion is important and current waiting times need to be
taken into consideration. Increased psychological input is essential as an initial
delay in the process may be associated with poor outcome.
WS8.2 Pulmonary arterial hypertension in adult CF lung
transplantation candidates
L. Fila1, A. Grandcourtova1, L. Valentova Bartakova1. 1Faculty Hospital Motol,
Pulmonary Department, Prague, Czech Republic
Objectives: To evaluate factors associated with pulmonary arterial hypertension
(PAH) in cystic ﬁbrosis (CF) lung transplant (LuTx) candidates.
Methods: Demographic and functional parameters in adult CF LuTx candidates
included on waiting list during 2009–2013 period were analyzed.
Results: 19 subjects (10 males and 9 females) with mean (±SD) age 28.9±8.4 years
were included into study. Mean (±SD) values of forced expiratory volume in 1 sec.
(FEV1), partial pressure of oxygen and carbon dioxide in arterial blood (paO2
and paCO2), six-minute walking distance (6-MWD) and mean pulmonary artery
pressure (MAP) were 23±5% pred., 7.30±0.86 kPa, 5.04±0.76 kPa, 297±86 m and
26±8mmHg, respectively. Correlations of FEV1 (r = −0.495; p = 0.031) and paCO2
(r = 0.463; p = 0.041) with MAP were found, whereas remaining parameters did not
correlate with MAP. In regression analysis, only FEV1 tended do predict (p = 0.057)
MAP value. Taken FEV1 parameter as a cut-off, value <20% pred. had sensitivity,
speciﬁcity and accuracy of 66.7%, 100.0% and 89.5%, respectively (p = 0.004 in
Fisher’s exact test) for MAP value 25mmHg. ROC for this FEV1 cut-off value
was 0.699 (p = 0.11).
Conclusion: Presence of PAH in adult CF LuTx candidates is associated mainly
with very severe airway obstruction (FEV1 <20% pred.).
WS8.3 Extracorporeal life support as a bridge to lung transplantation:
outcome in cystic ﬁbrosis recipients
I. Inci1, U. Bu¨rgi2, C. Benden2, L.C. Huber2, P. Kestenholz1, W. Weder1.
1Division of Thoracic Surgery, University Hospital, Zurich, Switzerland; 2Division
of Pulmonary Medicine, University Hospital, Zurich, Switzerland
Objectives: We investigated the early and mid-term outcome following lung
transplantation (LuTX) in patients with end-stage cystic ﬁbrosis (CF) lung dis-
ease bridged with extracorporeal life support (ECLS) to LuTX in comparison to
CF patients not requiring ECLS to LuTX.
Methods: We reviewed all 186 lung transplants performed between 01/2007 and
10/2013 at our institution. 30 patients required ECLS as bridge to LuTX, 12 of
which had CF.
Results: The subgroup of CF patients (n = 12) included 8 females, median
age 29 years (range 14−56). Venovenous extracorporeal membrane oxygenation
(ECMO) was used in 6, venoarterial in 1, interventional lung assist device in 1,
and stepwise combination of them in 4 recipients. Primary LuTX was performed
in 10 and re-transplantation in 2 cases. Lobar LuTX was performed in 4 recipients.
Success rate for bridging was 92% (12/13), only one patient died on ECMO while on
the waiting list. Median duration of ECLS was 23 days (range 1−81). Two patients
were kept awake on ECLS. Six patients required ECMO in the postoperative period
(median 2 days, range 1−9). 30-day, 1-year, and 2-year survival was 92%, 79%, and
79% respectively in CF patients on ECLS in comparison to 100%, 81%, and 78%,
respectively in CF patients (n = 39) not requiring ECLS (p = 0.35, Long Rank).
Conclusion: In carefully selected CF patients ECLS as a bridge to LuTX can
produce similar early and mid-term outcomes compared to CF recipients not
requiring ECLS a bridge to LuTX.
WS8.4 Extracorporeal life support in cystic ﬁbrosis; a single centre
experience
D. Keating1, F. Finlayson1, E. Williams1, D. Edgeworth1, T. Kotsimbos1,
J.W. Wilson1. 1Alfred Hospital, Allergy, Immunology and Respiratory Medicine,
Melbourne, Australia
Objectives: To assess our outcomes and indicators of ECMO survival.
Methods:We retrospectively analysed data from six CF patients who had undergone
ECMO at our hospital since 2010.
Results: See the table.
Table: ECMO patient details
Patient FEV1
% Pd
SOFA Precipitant Days to
ECMO
NIV (hrs)/
Vent (d)
ECMO
(d)
Outcome
1 46 9 Infection 11 114/1 32 Died
2 27 8 Infection 3 48/0 8 LTx
3 49 12 Infection &
Pregnancy
3 72/1 3 LTx
4 35 12 Infection &
Pneumothorax
27 24/1 8 LTx
5 85 10 H1N1 4 192/1 1 Died
6 46 12 Haemoptysis &
Pneumothorax
3 0/2 1 Died
Conclusion: APACHEII scores did not identify survivors but low SOFA scores
indicate ECMO tolerance. Patients retrieved for ECMO from other hospitals were
longer on NIV or intubated and tolerated ECMO poorly suggesting centres with
more experience of unwell CF patients identify ECMO candidates better. Only
1 of 6 patients met lung transplant (LTx) assessment criteria meaning ECMO
decisions must be considered early if we are to identify recoverable patients. All
our patients were exclusively women suggesting their known predilection for rapid
clinical decline means they are overrepresented in our ECMO recipients and should
be considered for ECMO earlier in the course of their disease.
